Evidence map›Paper›PMID 19255316›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

Malignant pleural mesothelioma.

Anne S Tsao, Ignacio Wistuba, Jack A Roth, Hedy Lee Kindler

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03918252 (Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma), which is not on this map. Cited by 149 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 4 pooled it
29.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03918252 phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

TypeinterventionalSponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRan2019 to 2028Enrolled30ConditionsMesotheliomaArmsNivolumab Injection, Ipilimumab Injection
3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 4 syntheses or guidelines pooled it, 467 citations in OpenAlex.

  1. Pooled it
  2. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016
    Guideline
  3. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
    Pooled it
  4. SEOM guidelines for the treatment of malignant pleural mesothelioma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011
    Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2010
    Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anne S TsaoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA. astsao@mdanderson.org
Ignacio Wistuba
Jack A Roth
Hedy Lee Kindler
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000 people each year in the United States. Although MPM is an extremely difficult disease to treat, with the median overall survival ranging between 9 and 17 months regardless of stage, there has been significant progress over the last few years that has reshaped the clinical landscape. This article will provide a comprehensive discussion of the latest developments in the treatment of MPM. We will provide an update of the major clinical trials that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript.

Indexed as

HumansMesotheliomaPleural Effusion, Malignant

Identifiers

PMID19255316
PMCPMC4881753
OpenAlexW2095824051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.